上海金畔生物科技有限公司为生命科学和医药研发人员提供生物活性分子抑制剂、激动剂、特异性抑制剂、化合物库、重组蛋白，专注于信号通路和疾病研究领域。
Pirarubicin Hydrochloride (Synonyms: 盐酸吡柔比星; THP Hydrochloride) 纯度: 98.51%
Pirarubicin Hydrochloride (THP Hydrochloride) 是一种蒽环类抗生素，为拓扑异构酶 II (topoisomerase II) 的抑制剂，可用于各种癌症尤其是实体瘤的研究。
Pirarubicin Hydrochloride Chemical Structure
CAS No. : 95343-20-7
| 规格 | 价格 | 是否有货 | 数量 |
|---|---|---|---|
| 10 mM * 1 mL in DMSO | ￥605 | In-stock | |
| 10 mg | ￥550 | In-stock | |
| 50 mg | ￥2100 | In-stock | |
| 100 mg | ￥3720 | In-stock | |
| 200 mg | 询价 | ||
| 500 mg | 询价 |
* Please select Quantity before adding items.
Pirarubicin Hydrochloride 相关产品
•相关化合物库:
- Covalent Screening Library Plus
- Natural Product Like Compound Library
- Drug Repurposing Compound Library Plus
- FDA-Approved Drug Library Plus
- FDA-Approved Drug Library Mini
- Bioactive Compound Library Plus
- Anti-Infection Compound Library
- Cell Cycle/DNA Damage Compound Library
- FDA-Approved Drug Library
- Anti-Cancer Compound Library
- Autophagy Compound Library
- Anti-Aging Compound Library
- Drug Repurposing Compound Library
- Covalent Screening Library
- Antibacterial Compound Library
- Anti-COVID-19 Compound Library
- NMPA-Approved Drug Library
- FDA Approved & Pharmacopeial Drug Library
- Antibiotics Library
- Anti-Lung Cancer Compound Library
- Anti-Blood Cancer Compound Library
- Rare Diseases Drug Library
- Children’s Drug Library
| 生物活性 |
Pirarubicin Hydrochloride is an anthracycline antibiotics, acts as a topoisomerase II inhibitor, and is a widely used for treatment of various cancers, in particular, solid tumors. |
||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| IC50 & Target |
|
||||||||||||||||
| 体外研究 (In Vitro) |
Pirarubicin is a topoisomerase II inhibitor[1]. Pirarubicin shows inhibitory activities against M5076 and Ehrlich cells, with IC50s of 0.366 and 0.078 μM, respectively. The cytotoxicity of Pirarubicin toward M5076 cells is lower than toward Ehrlich cells, and this is due to the much lower expression of topoisomerase II in M5076 cells than in Ehrlich cells[2]. Pirarubicin (2.5, 5, 10 μg/mL) significantly induces autophagy in a dose dependent manner in bladder cancer (T24, EJ, 5637, J82 and UM-UC-3) cells. Furthmore, Pirarubicin (5 μg/mL) induces apoptosis through inhibition of mTOR/p70S6K/4E-BP1 in bladder cancer cells, and this effect is enhanced by inhibition of autophagy[3]. 上海金畔生物科技有限公司 has not independently confirmed the accuracy of these methods. They are for reference only. |
||||||||||||||||
| 体内研究 (In Vivo) |
Pirarubicin (18 mg/kg, i.v.) significantly elevates serum level of BNP, CK-MB, CTnT, LDH, and MDA compared with those in the control group in acute cardiac toxicity rats. Pirarubicin also lowers heart rate, and depresses R-wave voltage, and prolongation of QT intervals in the acute cardiac toxicity model[4]. 上海金畔生物科技有限公司 has not independently confirmed the accuracy of these methods. They are for reference only. |
||||||||||||||||
| Clinical Trial |
|
||||||||||||||||
| 分子量 |
664.10 |
||||||||||||||||
| Formula |
C32H38ClNO12 |
||||||||||||||||
| CAS 号 |
95343-20-7 |
||||||||||||||||
| 中文名称 |
盐酸吡柔比星；盐酸吡喃阿霉素；盐酸吡柔吡星 |
||||||||||||||||
| 运输条件 |
Room temperature in continental US; may vary elsewhere. |
||||||||||||||||
| 储存方式 |
4°C, sealed storage, away from moisture and light *In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light) |
||||||||||||||||
| 溶解性数据 |
In Vitro:
DMSO : 20.83 mg/mL (31.37 mM; Need ultrasonic) H2O : < 0.1 mg/mL (ultrasonic;warming;heat to 60°C) (insoluble) 配制储备液
*
请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。 In Vivo:
请根据您的实验动物和给药方式选择适当的溶解方案。以下溶解方案都请先按照 In Vitro 方式配制澄清的储备液，再依次添加助溶剂： ——为保证实验结果的可靠性，澄清的储备液可以根据储存条件，适当保存；体内实验的工作液，建议您现用现配，当天使用； 以下溶剂前显示的百
|
||||||||||||||||
| 参考文献 |
|
| Cell Assay [3] |
MTS is used to analyze cell survival. Briefly, cells are plated in 96-well plates in triplicate at 2 × 103 cells per well and cultured in growth medium. Then cells are treated with pirarubicin at different concentrations (2.5 μg/mL, 5 μg/mL, 10 μg/mL) for 24 h. MTS reagent (5 mg/mL) is added and incubated at 37°C for 4 h. The absorbance is monitored at 490 nm using a microplate reader[3]. 上海金畔生物科技有限公司 has not independently confirmed the accuracy of these methods. They are for reference only. |
|---|---|
| Animal Administration [4] |
An acute cardiac toxicity model is established by a single dose of 18 mg/kg pirarubicin through the caudal vein injection. Thirty-six rats are randomized equally to six groups: normal control, cardiac injury (THP) model, dexrazoxane (180 mg/kg), low-dose rutin (25 mg/kg), middle-dose rutin (50 mg/kg), and high-dose rutin (100 mg/kg). Rats in the rutin-treated group are administered different doses of rutin and CMC-Na for 7 days by gavage and a single dose of 18 mg/kg pirarubicin through caudal vein injection. Rats in the dexrazoxane-treated group receive sodium carboxymethylcellulose (CMC-Na) by gavage for six days. 40 mg/kg dexrazoxane is then administered to rats by intraperitoneal injection and 18 mg/kg pirarubicin is administered by caudal vein injection on day 7. Rats in the THP model group receive CMC-Na by gavage for seven days, followed by pirarubicin 18 mg/kg through the caudal vein injection on day 7. Rats in the normal control group receive CMC-Na by gavage for seven days, followed by saline through caudal vein injection on day 7[4]. 上海金畔生物科技有限公司 has not independently confirmed the accuracy of these methods. They are for reference only. |
| 参考文献 |
|
所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务
